InnovAge Opens Fiscal 2027 With Street Revenue Bar Set Below Its Own Guidance

InnovAge enters its first report of fiscal 2027 with an unusual setup: management has guided to more revenue than Wall Street is willing to model, yet the stock has slid sharply since that guidance arrived. The September quarter is the opening chapter of what the company now calls InnovAge 3.0, its pivot from turnaround to growth, and it is the first test of whether profits can keep rising after the generous rate tailwinds of fiscal 2026 fade.

Analysts expect earnings of $0.11 per share on revenue of $255.2 million. That would be an 83% jump from the $0.06 earned a year ago, on revenue growth of about 8%. The profit comparison looks dramatic, but the revenue figure is the more revealing number. It sits below the $262.0 million InnovAge booked last quarter, implying a sequential step down, and it annualizes to roughly $1.02 billion. Management guided fiscal 2027 revenue to $1.050 billion to $1.085 billion, while the full-year consensus of $1.040 billion sits below even the low end of that range. Either analysts are building in caution about rates that have not been set, or they are leaving room for an upside surprise.

That caution has a clear source. On the last call, management confirmed the more temperate rate environment it had flagged for two quarters: Medicare net rates up only 1.5% to 2.0%, Medicaid increases in the low single digits, and the V28 risk model moving to a 50/50 blend in January 2027. More important, California and Colorado, which together account for roughly 70% of census, had not finalized rate-setting amid state budget pressure. Any update on those two states may matter more than the quarter itself, since a disappointing rate would squeeze margins on most of the business while a settled, acceptable rate would remove the biggest unknown hanging over the guidance.

With rate help shrinking, management conceded that earnings growth now depends on execution, which puts census and center-level margins at the center of this report. The company guided census to 8,625 to 8,850 participants by year end, up 5% to 7.5% from 8,230, so steady enrollment gains this quarter would validate the growth framing. On costs, center-level contribution margin reached 23.9% in the fourth quarter, down about 30 basis points from the third, and adjusted EBITDA fell to $24.3 million from $30.5 million. A rebound toward the pace needed for the $105 million to $115 million EBITDA target, which implies margins above 10%, would suggest the fourth-quarter dip was noise. Another sequential slip would raise doubts about whether margin gains can continue without rate support. Early evidence that the AI consultation and medication optimization tools are trimming specialist referrals and pharmacy spending would help, as would clean results free of the litigation accruals that pushed fiscal 2026 to a slight net loss.

The market has not given InnovAge the benefit of the doubt. Shares are down about 18% since the last report against a roughly flat S&P 500, and at $9.55 the stock trades much nearer its post-earnings low of $8.40 than its $12.20 high, though it remains above its 200-day moving average. Sentiment has improved modestly, roughly doubling from the prior quarter but still only mildly bullish, which suggests skepticism rather than enthusiasm.

After a year of repeated guidance raises, the bar here is less about a headline beat than about durability. If InnovAge can show steady census growth, stable center margins and reassuring news on California and Colorado rates, the gap between its guidance and Street models may start to close. If margins slip again or state rates come in light, the market will conclude the turnaround profits were built on rate tailwinds that are now gone.

This earnings preview was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.